# Souhrnná statistika - kvantitativní výsledky

## Cyklus EHK: AKS4/26 - Analyty krevního séra

Stop termín: 2.10.2026

Nastavení: skupiny - M (princip měření); Slovensko; minimální četnost skupin n = 5

| | | |
|---|---|---|
| RoM = robustní průměr | AV = vztažná hodnota | $D_{max}$ = přijatelný rozdíl |
| SD = směrodatná odchylka | CRV = certifikovaná referenční hodnota | LL = dolní mez |
| CV = variační koeficient | CVP = konsenzus všech účastníků | UL = horní mez |
| $N_{tot}$ = celkový počet výsledků | CVPG = konsenzus skupin účastníků | $N_{eva}$ = počet hodnocených výsledků |
| $N_{out}$ = počet výsledků vyloučených před výpočtem | $U_{AV}$ = rozšířená nejistota vztažné hodnoty (k = 2) | $N_{suc}$ = počet úspěšných výsledků |
| | | $S_{rel}$ = relativní úspěšnost |

| Zkouška / Vzorek / Skupina | [jednotka] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Srovnatelnost AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Návaznost AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (22) **α-amyláza** | [µkat/L] | | | | 64 | | | | | | | 64 | 64 | 100 | | | | | | 0 | | |
| **Vzorek A** | | | | | | | | | | | | 64 | 64 | 100 | | | | | | 0 | | |
| (0) Neuvedeno | | 1,91 | 0,078 | 4,1 | 64 | 0 | CVP 1,91 | 0,011 | 13% | 1,66 | 2,16 | 64 | | | | | | | | | | |
| **Vzorek B** | | | | | | | | | | | | 64 | 64 | 100 | | | | | | 0 | | |
| (0) Neuvedeno | | 1,35 | 0,056 | 4,1 | 64 | 0 | CVP 1,35 | 0,007 | 13% | 1,17 | 1,53 | 64 | | | | | | | | | | |
| (35) **α-amyláza pankreatická** | [µkat/L] | | | | 17 | | | | | | | 17 | 17 | 100 | | | | | | 0 | | |
| **Vzorek A** | | | | | | | | | | | | 17 | 17 | 100 | | | | | | 0 | | |
| (0) Neuvedeno | | 1,26 | 0,035 | 2,8 | 17 | 0 | CVP 1,29 | 0,013 | 18% | 1,05 | 1,53 | 17 | | | | | | | | | | |
| **Vzorek B** | | | | | | | | | | | | 17 | 17 | 100 | | | | | | 0 | | |
| (0) Neuvedeno | | 0,782 | 0,025 | 3,2 | 17 | 0 | CVP 0,802 | 0,009 | 18% | 0,657 | 0,947 | 17 | | | | | | | | | | |
| (32) **γ-globulin (elfo)** | [-] | | | | 11 | | | | | | | 11 | 10 | 91 | | | | | | 0 | | |
| **Vzorek A** | | | | | | | | | | | | 11 | 11 | 100 | | | | | | 0 | | |
| (0) Neuvedeno | | 0,122 | 0,015 | 12 | 11 | 0 | CVP 0,124 | 0,004 | 30% | 0,086 | 0,162 | 11 | | | | | | | | | | |
| **Vzorek B** | | | | | | | | | | | | 11 | 10 | 91 | | | | | | 0 | | |
| (0) Neuvedeno | | 0,125 | 0,024 | 19 | 11 | 0 | CVP 0,124 | 0,004 | 30% | 0,086 | 0,162 | 11 | | | | | | | | | | |
| (10) **Albumin** | [g/L] | | | | 63 | | | | | | | 63 | 63 | 100 | | | | | | 0 | | |
| **Vzorek A** | | 44,7 | 1,4 | 3,1 | 63 | | CVP 45,2 | 0,15 | 10% | 40,6 | 49,8 | 63 | 63 | 100 | | | | | | 0 | | |
| (1) BCG | | 44,8 | 1,4 | 3 | 60 | 0 | | | | | | 60 | | | | | | | | | | |
| Ostatní | | | | | 3 | 0 | | | | | | 3 | | | | | | | | | | |
| | | | | | | | 3x 2 | | | | | | | | | | | | | | | |
| **Vzorek B** | | 41,8 | 1,3 | 3,2 | 63 | | CVP 42,4 | 0,16 | 10% | 38,1 | 46,7 | 63 | 63 | 100 | | | | | | 0 | | |
| (1) BCG | | 41,9 | 1,3 | 3 | 60 | 0 | | | | | | 60 | | | | | | | | | | |
| Ostatní | | | | | 3 | 0 | | | | | | 3 | | | | | | | | | | |
| | | | | | | | 3x 2 | | | | | | | | | | | | | | | |
| (31) **Albumin (elfo)** | [-] | | | | 11 | | | | | | | 11 | 11 | 100 | | | | | | 0 | | |
| **Vzorek A** | | | | | | | | | | | | 11 | 11 | 100 | | | | | | 0 | | |
| (0) Neuvedeno | | 0,645 | 0,051 | 8 | 11 | 0 | CVP 0,641 | 0,009 | 15% | 0,544 | 0,738 | 11 | | | | | | | | | | |
| **Vzorek B** | | | | | | | | | | | | 11 | 11 | 100 | | | | | | 0 | | |
| (0) Neuvedeno | | 0,644 | 0,049 | 7,5 | 11 | 0 | CVP 0,642 | 0,009 | 15% | 0,545 | 0,739 | 11 | | | | | | | | | | |
| (21) **ALP** | [µkat/L] | | | | 64 | | | | | | | 61 | 56 | 92 | | | | | | 0 | | |
| **Vzorek A** | | 2,53 | 0,29 | 11 | 64 | | | | | | | 61 | 57 | 93 | | | | | | 0 | | |
| (3) IFCC metoda; (1) Abbott | | 2,71 | 0,055 | 2 | 11 | 0 | CVPG 2,69 | 0,022 | 14% | 2,31 | 3,07 | 11 | | | | | | | | | | |
| (3) IFCC metoda; (58) Beckman Coulter (AU) | | 2,7 | 0,14 | 5,3 | 19 | 0 | CVPG 2,65 | 0,039 | 14% | 2,27 | 3,03 | 19 | | | | | | | | | | |
| (3) IFCC metoda; (60) Roche | | 2,27 | 0,092 | 4 | 21 | 0 | CVPG 2,21 | 0,019 | 14% | 1,9 | 2,52 | 21 | | | | | | | | | | |
| Ostatní | | | | | 13 | 0 | | | | | | 10 | | | | | | | | | | |
| | | | | | | | 3x 3/12, 2x 3/46, 4x 3/162, 1x 3/177, 3x 3/178 | | | | | | | | | | | | | | | |
| **Vzorek B** | | 1,44 | 0,14 | 9,5 | 64 | | | | | | | 61 | 56 | 92 | | | | | | 0 | | |
| (3) IFCC metoda; (1) Abbott | | 1,56 | 0,035 | 2,3 | 11 | 0 | CVPG 1,55 | 0,016 | 14% | 1,33 | 1,77 | 11 | | | | | | | | | | |
| (3) IFCC metoda; (58) Beckman Coulter (AU) | | 1,49 | 0,062 | 4,2 | 19 | 0 | CVPG 1,47 | 0,02 | 14% | 1,26 | 1,68 | 19 | | | | | | | | | | |
| (3) IFCC metoda; (60) Roche | | 1,34 | 0,056 | 4,2 | 21 | 0 | CVPG 1,31 | 0,011 | 14% | 1,12 | 1,5 | 21 | | | | | | | | | | |

# Souhrnná statistika - kvantitativní výsledky

## Cyklus EHK: AKS4/26 - Analyty krevního séra

Stop termín: 2.10.2026

Nastavení: skupiny - M (princip měření); Slovensko; minimální četnost skupin n = 5

| Zkouška / Vzorek / Skupina | [jednotka] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Srovnatelnost | | | | | | | | Návaznost | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
| Ostatní | | | | | 13 | 0 | | | | | | 10 | | | | | | | | | | |
| | | | | | | | 3x 3/12, 2x 3/46, 4x 3/162, 1x 3/177, 3x 3/178 | | | | | | | | | | | | | | | |
| (24) **ALT** | [µkat/L] | | | | 67 | | | | | | | 67 | 62 | 93 | | | | | | 0 | | |
| **Vzorek A** | | | | | | | | | | | | 67 | 67 | 100 | | | | | | 0 | | |
| (0) Neuvedeno | | 1,52 | 0,071 | 4,7 | 67 | 0 | CVP | 1,53 | 0,008 | 13% | 1,33 | 1,73 | 67 | | | | | | | | | |
| **Vzorek B** | | | | | | | | | | | | 67 | 62 | 93 | | | | | | 0 | | |
| (0) Neuvedeno | | 0,754 | 0,048 | 6,3 | 67 | 0 | CVP | 0,77 | 0,005 | 13% | 0,669 | 0,871 | 67 | | | | | | | | | |
| (23) **AST** | [µkat/L] | | | | 66 | | | | | | | 66 | 66 | 100 | | | | | | 0 | | |
| **Vzorek A** | | | | | | | | | | | | 66 | 66 | 100 | | | | | | 0 | | |
| (0) Neuvedeno | | 3,09 | 0,13 | 4,3 | 66 | 0 | CVP | 3,12 | 0,017 | 14% | 2,68 | 3,56 | 66 | | | | | | | | | |
| **Vzorek B** | | | | | | | | | | | | 66 | 66 | 100 | | | | | | 0 | | |
| (0) Neuvedeno | | 2,07 | 0,079 | 3,8 | 66 | 0 | CVP | 2,08 | 0,009 | 14% | 1,78 | 2,38 | 66 | | | | | | | | | |
| (13) **Bilirubin celkový** | [µmol/L] | | | | 66 | | | | | | | 63 | 63 | 100 | | | | | | 66 | 66 | 100 |
| **Vzorek A** | | 126 | 8,8 | 7 | 66 | | | | | | | 63 | 63 | 100 | CRV | 121,5 | 2,8 | 26% | 89,9 | 154 | 66 | 66 | 100 |
| (2) DCA, DPD | | 125 | 8,1 | 6,5 | 56 | 0 | | | | | | | | | | | | | | | 56 | |
| (2) DCA, DPD; (1) Abbott | | 131 | 1,7 | 1,3 | 9 | 0 | CVPG | 132 | 1 | 12% | 116 | 148 | 9 | | | | | | | | | |
| (2) DCA, DPD; (58) Beckman Coulter (AU) | | 128 | 4,1 | 3,2 | 18 | 0 | CVPG | 128 | 1,1 | 12% | 112 | 144 | 18 | | | | | | | | | |
| (2) DCA, DPD; (60) Roche | | 117 | 2,5 | 2,1 | 23 | 0 | CVPG | 115 | 0,55 | 12% | 101 | 129 | 23 | | | | | | | | | |
| Ostatní | | | | | 10 | 0 | | | | | | 13 | | | | | | | | 10 | | |
| | | | | | | | 2x 1/1, 1x 1/46, 1x 1/58, 3x 2/12, 3x 2/178, 2x 4/162, 1x 4/177, 1x 99/46, 2x 99/162 | | | | | | | | 4x 1, 3x 4, 3x 99 | | | | | | | |
| **Vzorek B** | | 60,2 | 4,5 | 7,5 | 66 | | | | | | | 63 | 63 | 100 | CRV | 58,6 | 1,3 | 26% | 43,3 | 73,9 | 66 | 66 | 100 |
| (2) DCA, DPD | | 59,6 | 4,4 | 7,4 | 56 | 0 | | | | | | | | | | | | | | | 56 | |
| (2) DCA, DPD; (1) Abbott | | 61,5 | 1,3 | 2,1 | 9 | 0 | CVPG | 62,3 | 0,47 | 12% | 54,8 | 69,8 | 9 | | | | | | | | | |
| (2) DCA, DPD; (58) Beckman Coulter (AU) | | 62,7 | 1,8 | 2,9 | 18 | 0 | CVPG | 62,6 | 0,57 | 12% | 55 | 70,2 | 18 | | | | | | | | | |
| (2) DCA, DPD; (60) Roche | | 55,3 | 1 | 1,9 | 23 | 0 | CVPG | 54,8 | 0,27 | 12% | 48,2 | 61,4 | 23 | | | | | | | | | |
| Ostatní | | | | | 10 | 0 | | | | | | 13 | | | | | | | | 10 | | |
| | | | | | | | 2x 1/1, 1x 1/46, 1x 1/58, 3x 2/12, 3x 2/178, 2x 4/162, 1x 4/177, 1x 99/46, 2x 99/162 | | | | | | | | 4x 1, 3x 4, 3x 99 | | | | | | | |
| (14) **Bilirubin přímý** | [µmol/L] | | | | 48 | | | | | | | 45 | 33 | 73 | | | | | | 0 | | |
| **Vzorek A** | | 11,2 | 4 | 36 | 48 | | | | | | | 45 | 36 | 80 | | | | | | 0 | | |
| (2) DCA, DPD; (1) Abbott | | 6,7 | 0,44 | 6,6 | 8 | 0 | CVPG | 6,73 | 0,094 | 20% | 5,38 | 8,08 | 8 | | | | | | | | | |
| (2) DCA, DPD; (58) Beckman Coulter (AU) | | 13 | 1,7 | 13 | 19 | 0 | CVPG | 12,8 | 0,58 | 20% | 10,2 | 15,4 | 19 | | | | | | | | | |
| (2) DCA, DPD; (60) Roche | | 15,6 | 1,4 | 9,1 | 8 | 0 | CVPG | 13,9 | 0,48 | 20% | 11,1 | 16,7 | 8 | | | | | | | | | |
| Ostatní | | | | | 13 | 0 | | | | | | 10 | | | | | | | | | | |
| | | | | | | | 1x 1/1, 4x 1/60, 2x 2/12, 1x 2/178, 2x 4/162, 1x 4/177, 2x 99/162 | | | | | | | | | | | | | | | |
| **Vzorek B** | | 11,6 | 3,7 | 32 | 48 | | | | | | | 45 | 37 | 82 | | | | | | 0 | | |
| (2) DCA, DPD; (1) Abbott | | 10,6 | 0,52 | 4,9 | 8 | 0 | CVPG | 10,7 | 0,15 | 20% | 8,56 | 12,9 | 8 | | | | | | | | | |
| (2) DCA, DPD; (58) Beckman Coulter (AU) | | 8,82 | 1,4 | 16 | 19 | 0 | CVPG | 8,6 | 0,4 | 20% | 6,88 | 10,4 | 19 | | | | | | | | | |
| (2) DCA, DPD; (60) Roche | | 17,1 | 2,7 | 16 | 8 | 0 | CVPG | 16,5 | 0,3 | 20% | 13,2 | 19,8 | 8 | | | | | | | | | |
| Ostatní | | | | | 13 | 0 | | | | | | 10 | | | | | | | | | | |
| | | | | | | | 1x 1/1, 4x 1/60, 2x 2/12, 1x 2/178, 2x 4/162, 1x 4/177, 2x 99/162 | | | | | | | | | | | | | | | |
| (9) **Celková bílkovina** | [g/L] | | | | 63 | | | | | | | 0 | | | | | | | | 63 | 63 | 100 |
| **Vzorek A** | | | | | | | | | | | | 0 | | | | | | | | 63 | 63 | 100 |
| (0) Neuvedeno | | 69,8 | 2,1 | 3 | 63 | 0 | | | | | | | | | CRV | 71,9 | 1,6 | 9% | 65,4 | 78,4 | 63 | |

# Souhrnná statistika - kvantitativní výsledky

## Cyklus EHK: AKS4/26 - Analyty krevního séra

Stop termín: 2.10.2026

Nastavení: skupiny - M (princip měření); Slovensko; minimální četnost skupin n = 5

| Zkouška / Vzorek / Skupina | [jednotka] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Srovnatelnost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Návaznost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Vzorek B** | | | | | | | | | | | | | 0 | | | | | | | | | 63 | 63 | 100 |
| (0) Neuvedeno | | 65,5 | 1,8 | 2,7 | 63 | 0 | | | | | | | | | | CRV | 67,2 | 1,8 | 9% | 61,1 | 73,3 | 63 | | |
| (26) **CK** | [µkat/L] | | | | 61 | | | | | | | | 61 | 59 | 97 | | | | | | | 0 | | |
| **Vzorek A** | | | | | | | | | | | | | 61 | 61 | 100 | | | | | | | 0 | | |
| (0) Neuvedeno | | 3,44 | 0,2 | 5,7 | 61 | 0 | CVP | 3,46 | 0,029 | 17% | 2,87 | 4,05 | 61 | | | | | | | | | | | |
| **Vzorek B** | | | | | | | | | | | | | 61 | 59 | 97 | | | | | | | 0 | | |
| (0) Neuvedeno | | 2,15 | 0,16 | 7,3 | 61 | 1 | CVP | 2,19 | 0,02 | 17% | 1,81 | 2,57 | 61 | | | | | | | | | | | |
| (2) **Draselný kation** | [mmol/L] | | | | 64 | | | | | | | | 64 | 64 | 100 | | | | | | | 0 | | |
| **Vzorek A** | | 4,74 | 0,089 | 1,9 | 64 | | CVP | 4,77 | 0,011 | 6% | 4,48 | 5,06 | 64 | 64 | 100 | | | | | | | 0 | | |
| (2) ISE s ředěním | | 4,74 | 0,082 | 1,7 | 56 | 0 | | | | | | | 56 | | | | | | | | | | | |
| (3) ISE bez ředění | | 4,73 | 0,15 | 3,1 | 8 | 0 | | | | | | | 8 | | | | | | | | | | | |
| **Vzorek B** | | 3,7 | 0,081 | 2,2 | 64 | | CVP | 3,73 | 0,009 | 6% | 3,5 | 3,96 | 64 | 64 | 100 | | | | | | | 0 | | |
| (2) ISE s ředěním | | 3,69 | 0,078 | 2,1 | 56 | 0 | | | | | | | 56 | | | | | | | | | | | |
| (3) ISE bez ředění | | 3,76 | 0,19 | 4,9 | 8 | 0 | | | | | | | 8 | | | | | | | | | | | |
| (5) **Fosfáty anorganické** | [mmol/L] | | | | 59 | | | | | | | | 59 | 56 | 95 | | | | | | | 0 | | |
| **Vzorek A** | | | | | | | | | | | | | 59 | 58 | 98 | | | | | | | 0 | | |
| (1) UV-molybdátová metoda | | 1,63 | 0,037 | 2,2 | 59 | 0 | CVP | 1,62 | 0,004 | 10% | 1,45 | 1,79 | 59 | | | | | | | | | | | |
| **Vzorek B** | | | | | | | | | | | | | 59 | 57 | 97 | | | | | | | 0 | | |
| (1) UV-molybdátová metoda | | 0,754 | 0,026 | 3,4 | 59 | 0 | CVP | 0,75 | 0,003 | 10% | 0,675 | 0,825 | 59 | | | | | | | | | | | |
| (27) **GGT** | [µkat/L] | | | | 64 | | | | | | | | 64 | 63 | 98 | | | | | | | 0 | | |
| **Vzorek A** | | | | | | | | | | | | | 64 | 64 | 100 | | | | | | | 0 | | |
| (0) Neuvedeno | | 1,72 | 0,054 | 3,1 | 64 | 0 | CVP | 1,73 | 0,007 | 11% | 1,53 | 1,93 | 64 | | | | | | | | | | | |
| **Vzorek B** | | | | | | | | | | | | | 64 | 63 | 98 | | | | | | | 0 | | |
| (0) Neuvedeno | | 0,912 | 0,028 | 3,1 | 64 | 0 | CVP | 0,922 | 0,004 | 11% | 0,82 | 1,03 | 64 | | | | | | | | | | | |
| (16) **Glukóza** | [mmol/L] | | | | 66 | | | | | | | | 66 | 61 | 92 | | | | | | | 0 | | |
| **Vzorek A** | | 6,42 | 0,18 | 2,8 | 66 | | CVP | 6,42 | 0,016 | 7% | 5,97 | 6,87 | 66 | 63 | 95 | | | | | | | 0 | | |
| (1) GOD fotometricky | | 6,5 | 0,31 | 4,7 | 18 | 0 | | | | | | | 18 | | | | | | | | | | | |
| (3) Metoda s hexokinázou | | 6,41 | 0,14 | 2,2 | 48 | 0 | | | | | | | 48 | | | | | | | | | | | |
| **Vzorek B** | | 3,85 | 0,12 | 3,2 | 66 | | CVP | 3,86 | 0,011 | 7% | 3,58 | 4,14 | 66 | 63 | 95 | | | | | | | 0 | | |
| (1) GOD fotometricky | | 3,9 | 0,18 | 4,7 | 18 | 0 | | | | | | | 18 | | | | | | | | | | | |
| (3) Metoda s hexokinázou | | 3,83 | 0,099 | 2,6 | 48 | 0 | | | | | | | 48 | | | | | | | | | | | |
| (7) **Hořčík celkový** | [mmol/L] | | | | 60 | | | | | | | | 60 | 55 | 92 | | | | | | | 0 | | |
| **Vzorek A** | | 1,04 | 0,027 | 2,6 | 60 | | CVP | 1,04 | 0,004 | 11% | 0,925 | 1,16 | 60 | 57 | 95 | | | | | | | 0 | | |
| (2) Fotometrie | | 1,04 | 0,028 | 2,7 | 48 | 0 | | | | | | | 48 | | | | | | | | | | | |
| (4) UV enzymová metoda | | 1,03 | 0,023 | 2,2 | 12 | 0 | | | | | | | 12 | | | | | | | | | | | |
| **Vzorek B** | | 0,486 | 0,018 | 3,7 | 60 | | CVP | 0,489 | 0,002 | 11% | 0,435 | 0,543 | 60 | 57 | 95 | | | | | | | 0 | | |
| (2) Fotometrie | | 0,489 | 0,017 | 3,4 | 48 | 0 | | | | | | | 48 | | | | | | | | | | | |
| (4) UV enzymová metoda | | 0,473 | 0,016 | 3,3 | 12 | 0 | | | | | | | 12 | | | | | | | | | | | |
| (3) **Chloridový anion** | [mmol/L] | | | | 64 | | | | | | | | 64 | 63 | 98 | | | | | | | 0 | | |
| **Vzorek A** | | 112 | 3 | 2,6 | 64 | | CVP | 112 | 0,45 | 7% | 104 | 120 | 64 | 64 | 100 | | | | | | | 0 | | |
| (3) ISE s ředěním | | 112 | 3 | 2,6 | 56 | 0 | | | | | | | 56 | | | | | | | | | | | |
| (4) ISE bez ředění | | 114 | 3,9 | 3,4 | 8 | 0 | | | | | | | 8 | | | | | | | | | | | |
| **Vzorek B** | | 99,2 | 2,7 | 2,8 | 64 | | CVP | 99,4 | 0,47 | 7% | 92,4 | 107 | 64 | 63 | 98 | | | | | | | 0 | | |
| (3) ISE s ředěním | | 99,2 | 2,9 | 2,9 | 56 | 0 | | | | | | | 56 | | | | | | | | | | | |
| (4) ISE bez ředění | | 100 | 3 | 3 | 8 | 0 | | | | | | | 8 | | | | | | | | | | | |

# Souhrnná statistika - kvantitativní výsledky

## Cyklus EHK: AKS4/26 - Analyty krevního séra

Stop termín: 2.10.2026

Nastavení: skupiny - M (princip měření); Slovensko; minimální četnost skupin n = 5

| Zkouška / Vzorek / Skupina | [jednotka] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Srovnatelnost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Návaznost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (15) **Cholesterol** | [mmol/L] | | | | 63 | | | | | | | | 0 | | | | | | | | | 63 | 58 | 92 |
| **Vzorek A** | | | | | | | | | | | | | 0 | | | | | | | | | 63 | 58 | 92 |
| (0) Neuvedeno | | 4,61 | 0,17 | 3,6 | 63 | 1 | | | | | | | | | | CRV | 4,823 | 0,048 | 9% | 4,38 | 5,26 | 63 | | |
| **Vzorek B** | | | | | | | | | | | | | 0 | | | | | | | | | 63 | 61 | 97 |
| (0) Neuvedeno | | 4,39 | 0,14 | 3,2 | 63 | 0 | | | | | | | | | | CRV | 4,54 | 0,045 | 9% | 4,13 | 4,95 | 63 | | |
| (30) **Cholinesteráza** | [µkat/L] | | | | 30 | | | | | | | | 30 | 28 | 93 | | | | | | | 0 | | |
| **Vzorek A** | | | | | | | | | | | | | 30 | 28 | 93 | | | | | | | 0 | | |
| (0) Neuvedeno | | 131 | 4,4 | 3,3 | 30 | 0 | CVP | 132 | 1,4 | 12% | 116 | 148 | 30 | | | | | | | | | | | |
| **Vzorek B** | | | | | | | | | | | | | 30 | 28 | 93 | | | | | | | 0 | | |
| (0) Neuvedeno | | 122 | 3,9 | 3,2 | 30 | 0 | CVP | 124 | 1,3 | 12% | 109 | 139 | 30 | | | | | | | | | | | |
| (19) **Kreatinin** | [µmol/L] | | | | 66 | | | | | | | | 0 | | | | | | | | | 66 | 66 | 100 |
| **Vzorek A** | | 329 | 10 | 3,1 | 66 | | | | | | | | 0 | | | CRV | 328,5 | 3,3 | 13% | 285 | 372 | 66 | 66 | 100 |
| (1) Jaffé | | 327 | 12 | 3,5 | 35 | 0 | | | | | | | | | | | | | | | | 35 | | |
| (3) Enzymové stanovení | | 331 | 8,5 | 2,6 | 31 | 0 | | | | | | | | | | | | | | | | 31 | | |
| **Vzorek B** | | 149 | 6,1 | 4,1 | 66 | | | | | | | | 0 | | | CRV | 148,8 | 1,5 | 13% | 129 | 169 | 66 | 66 | 100 |
| (1) Jaffé | | 150 | 7,1 | 4,8 | 35 | 0 | | | | | | | | | | | | | | | | 35 | | |
| (3) Enzymové stanovení | | 148 | 5,1 | 3,4 | 31 | 0 | | | | | | | | | | | | | | | | 31 | | |
| (17) **Kyselina močová** | [µmol/L] | | | | 63 | | | | | | | | 0 | | | | | | | | | 63 | 62 | 98 |
| **Vzorek A** | | | | | | | | | | | | | 0 | | | | | | | | | 63 | 63 | 100 |
| (0) Neuvedeno | | 260 | 7,5 | 2,9 | 63 | 0 | | | | | | | | | | CRV | 262,3 | 2,6 | 12% | 230 | 294 | 63 | | |
| **Vzorek B** | | | | | | | | | | | | | 0 | | | | | | | | | 63 | 62 | 98 |
| (0) Neuvedeno | | 194 | 6,7 | 3,5 | 63 | 0 | | | | | | | | | | CRV | 196,8 | 2 | 12% | 173 | 221 | 63 | | |
| (12) **Laktát** | [mmol/L] | | | | 34 | | | | | | | | 34 | 34 | 100 | | | | | | | 0 | | |
| **Vzorek A** | | 3,11 | 0,17 | 5,4 | 34 | | CVP | 3,15 | 0,023 | 15% | 2,67 | 3,63 | 34 | 34 | 100 | | | | | | | 0 | | |
| (1) UV enzymová metoda | | 3,06 | 0,2 | 6,6 | 13 | 0 | | | | | | | 13 | | | | | | | | | | | |
| (3) Fotometrická enzymová metoda | | 3,16 | 0,13 | 4,3 | 20 | 0 | | | | | | | 20 | | | | | | | | | | | |
| Ostatní | | | | | 1 | 0 | | | | | | | 1 | | | | | | | | | | | |
| | | | | | | | 1x 2 | | | | | | | | | | | | | | | | | |
| **Vzorek B** | | 2,31 | 0,11 | 4,9 | 34 | | CVP | 2,33 | 0,017 | 15% | 1,98 | 2,68 | 34 | 34 | 100 | | | | | | | 0 | | |
| (1) UV enzymová metoda | | 2,3 | 0,12 | 5,1 | 13 | 0 | | | | | | | 13 | | | | | | | | | | | |
| (3) Fotometrická enzymová metoda | | 2,33 | 0,091 | 3,9 | 20 | 0 | | | | | | | 20 | | | | | | | | | | | |
| Ostatní | | | | | 1 | 0 | | | | | | | 1 | | | | | | | | | | | |
| | | | | | | | 1x 2 | | | | | | | | | | | | | | | | | |
| (28) **LD** | [µkat/L] | | | | 48 | | | | | | | | 48 | 48 | 100 | | | | | | | 0 | | |
| **Vzorek A** | | | | | | | | | | | | | 48 | 48 | 100 | | | | | | | 0 | | |
| (0) Neuvedeno | | 3,23 | 0,13 | 4 | 48 | 0 | CVP | 3,23 | 0,017 | 14% | 2,77 | 3,69 | 48 | | | | | | | | | | | |
| **Vzorek B** | | | | | | | | | | | | | 48 | 48 | 100 | | | | | | | 0 | | |
| (0) Neuvedeno | | 2,46 | 0,11 | 4,3 | 48 | 0 | CVP | 2,47 | 0,014 | 14% | 2,12 | 2,82 | 48 | | | | | | | | | | | |
| (29) **Lipáza** | [µkat/L] | | | | 37 | | | | | | | | 31 | 31 | 100 | | | | | | | 0 | | |
| **Vzorek A** | | 1,48 | 0,16 | 11 | 37 | | | | | | | | 31 | 31 | 100 | | | | | | | 0 | | |
| (0) Neuvedeno; (1) Abbott | | 1,62 | 0,045 | 2,7 | 5 | 0 | CVPG | 1,6 | 0,037 | 18% | 1,31 | 1,89 | 5 | | | | | | | | | | | |
| (0) Neuvedeno; (58) Beckman Coulter (AU) | | 1,47 | 0,07 | 4,8 | 10 | 0 | CVPG | 1,47 | 0,019 | 18% | 1,2 | 1,74 | 10 | | | | | | | | | | | |
| (0) Neuvedeno; (60) Roche | | 1,07 | 0,03 | 2,8 | 6 | 0 | CVPG | 1,09 | 0,02 | 18% | 0,893 | 1,29 | 6 | | | | | | | | | | | |
| (0) Neuvedeno; (256) Roche (2) | | 1,51 | 0,16 | 11 | 6 | 0 | CVPG | 1,55 | 0,065 | 18% | 1,27 | 1,83 | 6 | | | | | | | | | | | |
| Ostatní | | | | | 10 | 0 | | | | | | | 4 | | | | | | | | | | | |
| | | | | | | | 2x 0/12, 2x 0/116, 4x 0/162, 2x 0/178 | | | | | | | | | | | | | | | | | |

# Souhrnná statistika - kvantitativní výsledky

## Cyklus EHK: AKS4/26 - Analyty krevního séra

Stop termín: 2.10.2026

Nastavení: skupiny - M (princip měření); Slovensko; minimální četnost skupin n = 5

| Zkouška / Vzorek / Skupina | [jednotka] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Srovnatelnost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Návaznost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Vzorek B** | | 0,871 | 0,077 | 8,8 | 37 | | | | | | | | 31 | 31 | 100 | | | | | | | 0 | | |
| (0) Neuvedeno; (1) Abbott | | 0,89 | 0,045 | 5 | 5 | 0 | CVPG | 0,888 | 0,015 | 18% | 0,728 | 1,05 | 5 | | | | | | | | | | | |
| (0) Neuvedeno; (58) Beckman Coulter (AU) | | 0,853 | 0,044 | 5,2 | 10 | 0 | CVPG | 0,85 | 0,014 | 18% | 0,697 | 1,01 | 10 | | | | | | | | | | | |
| (0) Neuvedeno; (60) Roche | | 0,752 | 0,018 | 2,4 | 6 | 0 | CVPG | 0,758 | 0,011 | 18% | 0,621 | 0,895 | 6 | | | | | | | | | | | |
| (0) Neuvedeno; (256) Roche (2) | | 0,91 | 0,045 | 4,9 | 6 | 0 | CVPG | 0,925 | 0,021 | 18% | 0,758 | 1,1 | 6 | | | | | | | | | | | |
| Ostatní | | | | | 10 | 0 | | | | | | | 4 | | | | | | | | | | | |
| | | | | | | | 2x 0/12, 2x 0/116, 4x 0/162, 2x 0/178 | | | | | | | | | | | | | | | | | |
| (8) **Lithium** | [mmol/L] | | | | 7 | | | | | | | | 7 | 4 | 57 | | | | | | | 0 | | |
| **Vzorek A** | | 1,36 | 0,059 | 4,4 | 7 | | CVP | 1,37 | 0,017 | 12% | 1,2 | 1,54 | 7 | 6 | 86 | | | | | | | 0 | | |
| (4) Fotometrie | | 1,36 | 0,059 | 4,4 | 6 | 0 | | | | | | | 6 | | | | | | | | | | | |
| Ostatní | | | | | 1 | 0 | | | | | | | 1 | | | | | | | | | | | |
| | | | | | | | 1x 3 | | | | | | | | | | | | | | | | | |
| **Vzorek B** | | 0,658 | 0,071 | 11 | 7 | | CVP | 0,625 | 0,014 | 12% | 0,55 | 0,7 | 7 | 5 | 71 | | | | | | | 0 | | |
| (4) Fotometrie | | 0,635 | 0,037 | 5,8 | 6 | 0 | | | | | | | 6 | | | | | | | | | | | |
| Ostatní | | | | | 1 | 0 | | | | | | | 1 | | | | | | | | | | | |
| | | | | | | | 1x 3 | | | | | | | | | | | | | | | | | |
| (18) **Močovina** | [mmol/L] | | | | 66 | | | | | | | | 0 | | | | | | | | | 66 | 65 | 98 |
| **Vzorek A** | | 11,4 | 0,39 | 3,4 | 66 | | | | | | | | 0 | | | CRV | 11,48 | 0,11 | 15% | 9,75 | 13,3 | 66 | 66 | 100 |
| (1) UV enzymová m. (GMD) | | 11,4 | 0,39 | 3,4 | 65 | 0 | | | | | | | | | | | | | | | | 65 | | |
| Ostatní | | | | | 1 | 0 | | | | | | | | | | | | | | | | 1 | | |
| | | | | | | | | | | | | | | | | 1x 2 | | | | | | | | |
| **Vzorek B** | | 5,18 | 0,23 | 4,4 | 66 | | | | | | | | 0 | | | CRV | 5,18 | 0,052 | 15% | 4,4 | 5,96 | 66 | 65 | 98 |
| (1) UV enzymová m. (GMD) | | 5,18 | 0,23 | 4,4 | 65 | 0 | | | | | | | | | | | | | | | | 65 | | |
| Ostatní | | | | | 1 | 0 | | | | | | | | | | | | | | | | 1 | | |
| | | | | | | | | | | | | | | | | 1x 2 | | | | | | | | |
| (11) **Osmolalita** | [mmol/kg] | | | | 19 | | | | | | | | 19 | 18 | 95 | | | | | | | 0 | | |
| **Vzorek A** | | | | | | | | | | | | | 19 | 18 | 95 | | | | | | | 0 | | |
| (0) Neuvedeno | | 294 | 4,3 | 1,4 | 19 | 0 | CVP | 292 | 1,1 | 5% | 277 | 307 | 19 | | | | | | | | | | | |
| **Vzorek B** | | | | | | | | | | | | | 19 | 18 | 95 | | | | | | | 0 | | |
| (0) Neuvedeno | | 253 | 4,6 | 1,8 | 19 | 0 | CVP | 252 | 0,98 | 5% | 239 | 265 | 19 | | | | | | | | | | | |
| (1) **Sodný kation** | [mmol/L] | | | | 64 | | | | | | | | 64 | 62 | 97 | | | | | | | 0 | | |
| **Vzorek A** | | 133 | 1,8 | 1,4 | 64 | | CVP | 134 | 0,23 | 4% | 128 | 140 | 64 | 64 | 100 | | | | | | | 0 | | |
| (2) ISE s ředěním | | 133 | 1,7 | 1,3 | 56 | 0 | | | | | | | 56 | | | | | | | | | | | |
| (3) ISE bez ředění | | 135 | 5,9 | 4,4 | 8 | 0 | | | | | | | 8 | | | | | | | | | | | |
| **Vzorek B** | | 120 | 1,9 | 1,6 | 64 | | CVP | 120 | 0,23 | 4% | 115 | 125 | 64 | 62 | 97 | | | | | | | 0 | | |
| (2) ISE s ředěním | | 120 | 1,7 | 1,4 | 56 | 0 | | | | | | | 56 | | | | | | | | | | | |
| (3) ISE bez ředění | | 122 | 4,4 | 3,7 | 8 | 0 | | | | | | | 8 | | | | | | | | | | | |
| (20) **Triacylglyceroly** | [mmol/L] | | | | 62 | | | | | | | | 0 | | | | | | | | | 62 | 62 | 100 |
| **Vzorek A** | | 1,47 | 0,098 | 6,7 | 62 | | | | | | | | 0 | | | CRV | 1,478 | 0,015 | 18% | 1,21 | 1,75 | 62 | 62 | 100 |
| (1) Fotometrické enzymové stan. (GPO-PAP) | | 1,46 | 0,097 | 6,6 | 60 | 0 | | | | | | | | | | | | | | | | 60 | | |
| Ostatní | | | | | 2 | 0 | | | | | | | | | | | | | | | | 2 | | |
| | | | | | | | | | | | | | | | | 2x 2 | | | | | | | | |
| **Vzorek B** | | 1,07 | 0,074 | 6,9 | 62 | | | | | | | | 0 | | | CRV | 1,069 | 0,011 | 18% | 0,876 | 1,27 | 62 | 62 | 100 |
| (1) Fotometrické enzymové stan. (GPO-PAP) | | 1,07 | 0,073 | 6,8 | 60 | 0 | | | | | | | | | | | | | | | | 60 | | |
| Ostatní | | | | | 2 | 0 | | | | | | | | | | | | | | | | 2 | | |
| | | | | | | | | | | | | | | | | 2x 2 | | | | | | | | |

# Souhrnná statistika - kvantitativní výsledky

## Cyklus EHK: AKS4/26 - Analyty krevního séra

Stop termín: 2.10.2026

Nastavení: skupiny - M (princip měření); Slovensko; minimální četnost skupin n = 5

| Zkouška / Vzorek / Skupina | [jednotka] | RoM | SD | CV [%] | $N_{tot}$ | $N_{out}$ | Srovnatelnost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] | Návaznost | AV | $U_{AV}$ | $D_{max}$ | LL | UL | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (4) **Vápník celkový** | [mmol/L] | | | | 61 | | | | | | | | 61 | 60 | 98 | | | | | | | 0 | | |
| **Vzorek A** | | 2,32 | 0,054 | 2,3 | 61 | | CVP | 2,31 | 0,006 | 7% | 2,14 | 2,48 | 61 | 60 | 98 | | | | | | | 0 | | |
| (3) Fotomet. s arsenazo III | | 2,31 | 0,06 | 2,6 | 39 | 0 | | | | | | | 39 | | | | | | | | | | | |
| (4) Fotomet. s NM-BAPTA | | 2,32 | 0,028 | 1,2 | 19 | 0 | | | | | | | 19 | | | | | | | | | | | |
| Ostatní | | | | | 3 | 0 | | | | | | | 3 | | | | | | | | | | | |
| | | | | | | | 2x 2, 1x 99 | | | | | | | | | | | | | | | | | |
| **Vzorek B** | | 2,51 | 0,06 | 2,4 | 61 | | CVP | 2,5 | 0,007 | 7% | 2,32 | 2,68 | 61 | 61 | 100 | | | | | | | 0 | | |
| (3) Fotomet. s arsenazo III | | 2,49 | 0,059 | 2,4 | 39 | 0 | | | | | | | 39 | | | | | | | | | | | |
| (4) Fotomet. s NM-BAPTA | | 2,52 | 0,029 | 1,2 | 19 | 0 | | | | | | | 19 | | | | | | | | | | | |
| Ostatní | | | | | 3 | 0 | | | | | | | 3 | | | | | | | | | | | |
| | | | | | | | 2x 2, 1x 99 | | | | | | | | | | | | | | | | | |
| (36) **Vápník ionizovaný** | [mmol/L] | | | | 11 | | | | | | | | 11 | 10 | 91 | | | | | | | 0 | | |
| **Vzorek A** | | 1,42 | 0,028 | 2 | 11 | | CVP | 1,42 | 0,013 | 10% | 1,27 | 1,57 | 11 | 10 | 91 | | | | | | | 0 | | |
| (2) ISE bez ředění | | 1,42 | 0,022 | 1,6 | 10 | 0 | | | | | | | 10 | | | | | | | | | | | |
| Ostatní | | | | | 1 | 0 | | | | | | | 1 | | | | | | | | | | | |
| | | | | | | | 1x 0 | | | | | | | | | | | | | | | | | |
| **Vzorek B** | | 1,62 | 0,036 | 2,2 | 11 | | CVP | 1,62 | 0,014 | 10% | 1,45 | 1,79 | 11 | 10 | 91 | | | | | | | 0 | | |
| (2) ISE bez ředění | | 1,63 | 0,031 | 1,9 | 10 | 0 | | | | | | | 10 | | | | | | | | | | | |
| Ostatní | | | | | 1 | 0 | | | | | | | 1 | | | | | | | | | | | |
| | | | | | | | 1x 0 | | | | | | | | | | | | | | | | | |
| (6) **Železo celkové** | [µmol/L] | | | | 57 | | | | | | | | 57 | 57 | 100 | | | | | | | 0 | | |
| **Vzorek A** | | 25,8 | 0,72 | 2,8 | 57 | | CVP | 25,8 | 0,084 | 15% | 21,9 | 29,7 | 57 | 57 | 100 | | | | | | | 0 | | |
| (2) Metoda s ferrozinem/ferenem | | 25,9 | 0,77 | 3 | 42 | 0 | | | | | | | 42 | | | | | | | | | | | |
| (4) Metoda s TPTZ | | 25,7 | 0,56 | 2,2 | 15 | 0 | | | | | | | 15 | | | | | | | | | | | |
| **Vzorek B** | | 20,8 | 0,5 | 2,4 | 57 | | CVP | 20,9 | 0,066 | 15% | 17,7 | 24,1 | 57 | 57 | 100 | | | | | | | 0 | | |
| (2) Metoda s ferrozinem/ferenem | | 20,8 | 0,56 | 2,7 | 42 | 0 | | | | | | | 42 | | | | | | | | | | | |
| (4) Metoda s TPTZ | | 20,8 | 0,25 | 1,2 | 15 | 0 | | | | | | | 15 | | | | | | | | | | | |